Syntara Limited has released a press release.
PXS Grants Exclusive Option to Develop High Payload Inhaler
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Syntara
- PXS Drug Decreases Tumour Burden in Liver Cancer Model
- PXS Sells Australian Distribution Rights for A$2m
- PXS Announces First Results in Bone Marrow Cancer Trial
- Quarterly Activity Report
- Appendix 4C - quarterly
Later from Syntara
- Pharmaxis Treatment to Prevent Wound and Burns Scars Clears
- PXS Cleared to Progress to Phase 2 Bone Marrow Cancer Trial
- PXS Doses First Patient in Phase 2 Bone Marrow Cancer Trial
- Appendix 4C Cash Flow Report
- FDA Clears PXS Cancer Drug for Phase 2 Liver Cancer Study
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara